Azithromycin hydrate

产品说明书

Print
Chemical Structure| 117772-70-0 同义名 : 阿奇霉素二水合物 ;CP-62993 dihydrate;Azithromycin Dihydrate
CAS号 : 117772-70-0
货号 : A385826
分子式 : C38H76N2O14
纯度 : 99%
分子量 : 785.015
MDL号 : MFCD01862248
存储条件:

Pure form Keep in dark place,Inert atmosphere,Room temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(133.76 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Azithromycin (Dihydrate) is an azalide, a subclass of macrolide antibiotics. It prevents bacteria from growing by interfering with their protein synthesis. It binds to the 50S subunit of the bacterial ribosome and thus inhibits translation of mRNA. Azithromycin is used to treat or prevent certain bacterial infections, most often those causing middle ear infections, strep throat, pneumonia, typhoid, bronchitis, and sinusitis[3]. Azithromycin dose-dependently augmented viral-induced IFNβ (interferons, IFNs) expression in asthmatic, but not in healthy bronchial epithelial cells. Clinically relevant concentrations of azithromycin produce MDA5-dependent, anti-viral, IFN-inducing effects in bronchial epithelium distinctly from asthmatic donors[4]. Azithromycin treatment induced a perturbation in the gut microbiota 14 days after randomization but did not have long-lasting effects on the gut microbiota composition[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00694694 Malaria Phase 3 Completed - Tanzania ... 展开 >> Teule Hospital Muheza, Tanga Region, Tanzania 收起 <<
NCT01235546 Endometritis ... 展开 >>Wound Infection Abscess Surgical Site Infection 收起 << Not Applicable Completed - United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, Louisiana Ochsner Clinic Foundation New Orleans, Louisiana, United States, 70121 United States, Mississippi University of Mississippi Medical Center Jackson, Mississippi, United States, 39216 United States, New York Columbia University New York, New York, United States, 10032 United States, North Carolina Mission Hospital Asheville, North Carolina, United States, 28801 University of North Carolina Chapel Hill, North Carolina, United States, 27599-7516 United States, Texas University of Texas Medical Branch Galveston, Texas, United States, 77555-0587 University of Texas Health Science Center at Houston Houston, Texas, United States, 77225 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 收起 <<
NCT02527005 Malaria Pregn... 展开 >>ant HIV 收起 << Phase 1 Completed - Nigeria ... 展开 >> University College Hospital, Ibadan, Oyo, Nigeria, 200001 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.27mL

0.25mL

0.13mL

6.37mL

1.27mL

0.64mL

12.74mL

2.55mL

1.27mL

参考文献

[1]Menzel M, Akbarshahi H, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 May 9;8(19):31601-31611.

[2]Vandooren J, Knoops S, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853.

[3]Bakheit AH, Al-Hadiya BM, Abd-Elgalil AA. Azithromycin. Profiles Drug Subst Excip Relat Methodol. 2014;39:1‐40

[4]Menzel M, Akbarshahi H, Tufvesson E, Persson C, Bjermer L, Uller L. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017;8(19):31601‐31611

[5]Wei S, Mortensen MS, Stokholm J, et al. Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial. EBioMedicine. 2018;38:265‐272